Current status is Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

119th CONGRESS

1st Session

H. R. 1143

1. Short title
2. Expanding coverage of the in-home administration of intravenous immune globulin under the Medicare program

1. Short title

This Act may be cited as the "Medicare IVIG Access Enhancement Act of 2025".

2. Expanding coverage of the in-home administration of intravenous immune globulin under the Medicare program

(a) In general - Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended—

(1) - in subsection (s)(2)(Z), by inserting "(and, beginning January 1, 2027, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)" after "primary immune deficiency diseases"; and

(2) - in subsection (zz), by inserting "(or, beginning January 1, 2027, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)" after "primary immune deficiency disease".

(b) Authority for variance in payments - Section 1842(o)(8) of the Social Security Act (42 U.S.C. 1395u(o)(8)) is amended by inserting "and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking)" after "of 2012".

119-HR1143

Medicare IVIG Access Enhancement Act of 2025

119th CONGRESS

1st Session

H. R. 1143

1. Short title

2. Expanding coverage of the in-home administration of intravenous immune globulin under the Medicare program